AR035071A1 - Compuestos para el tratamiento de la disfuncion endotelial; metodo para producir a dichos compuestos farmaceuticos; uso de dichos compuestos para la manufactura de un medicamento - Google Patents
Compuestos para el tratamiento de la disfuncion endotelial; metodo para producir a dichos compuestos farmaceuticos; uso de dichos compuestos para la manufactura de un medicamentoInfo
- Publication number
- AR035071A1 AR035071A1 ARP010105032A ARP010105032A AR035071A1 AR 035071 A1 AR035071 A1 AR 035071A1 AR P010105032 A ARP010105032 A AR P010105032A AR P010105032 A ARP010105032 A AR P010105032A AR 035071 A1 AR035071 A1 AR 035071A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- radical
- group
- treatment
- dysfunction
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title 2
- 230000004064 dysfunction Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- 229940125753 fibrate Drugs 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 210000002824 peroxisome Anatomy 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108091006084 receptor activators Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El compuesto comprende un activador del receptor activado de multiplicador de peroxisoma (PPAR) y una benzoquinona de fórmula (1) en la cual R1, R2 y R3 independientemente están formados por: un grupo alquilo C1-8, o un grupo alcoxi C1-8; R4 consiste en: un átomo de hidrógeno, un grupo hidrocarbilo C1-60, un radical OR5, un radical SR6, un radical N(R7) (R8); un grupo nitro, o un grupo carboxilo; R5, R6, R7 y R8 están formados por: un átomo de hidrógeno, o un grupo alquilo que contiene C1-20, O un precursor de los anteriores capaz de metabolizarse en un organismo humano o animal en dicha benzoquinona, o una sal farmacéuticamente aceptable de los anteriores. El activador PPAR es elegido entre un fibrato o tiazolidinediona. El uso de estos compuestos es útil como agente para el tratamiento y/o prevención de desórdenes por disfunción endotelial , tal como enfermedad cardiovascular, accidentes cerebro vascular e infarto miocardio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR1038A AUPR103800A0 (en) | 2000-10-26 | 2000-10-26 | Compositions for the treatment of endothelial dysfunction |
| AUPR3424A AUPR342401A0 (en) | 2001-02-28 | 2001-02-28 | Compositions for the treatment of endothelial dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035071A1 true AR035071A1 (es) | 2004-04-14 |
Family
ID=25646491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105032A AR035071A1 (es) | 2000-10-26 | 2001-10-26 | Compuestos para el tratamiento de la disfuncion endotelial; metodo para producir a dichos compuestos farmaceuticos; uso de dichos compuestos para la manufactura de un medicamento |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7410983B2 (es) |
| EP (1) | EP1328266B1 (es) |
| JP (1) | JP4236464B2 (es) |
| KR (1) | KR100862129B1 (es) |
| CN (1) | CN1220488C (es) |
| AR (1) | AR035071A1 (es) |
| AT (1) | ATE316787T1 (es) |
| AU (1) | AU2176502A (es) |
| BG (1) | BG65979B1 (es) |
| BR (1) | BR0114701A (es) |
| CA (1) | CA2426625C (es) |
| CY (1) | CY1105007T1 (es) |
| CZ (1) | CZ301282B6 (es) |
| DE (1) | DE60117046T2 (es) |
| DK (1) | DK1328266T3 (es) |
| DZ (1) | DZ3442A1 (es) |
| EE (1) | EE05281B1 (es) |
| ES (1) | ES2257457T3 (es) |
| HU (1) | HUP0303566A3 (es) |
| IL (2) | IL155524A0 (es) |
| MA (1) | MA25847A1 (es) |
| MX (1) | MXPA03003733A (es) |
| NO (1) | NO332260B1 (es) |
| PL (1) | PL212952B1 (es) |
| PT (1) | PT1328266E (es) |
| RU (1) | RU2003111175A (es) |
| SK (1) | SK287992B6 (es) |
| TN (1) | TNSN01151A1 (es) |
| WO (1) | WO2002034259A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE360417T1 (de) | 2001-07-11 | 2007-05-15 | Boehringer Ingelheim Pharma | Methode zur behandlung von zytokinvermittelten erkrankungen |
| AU2003208238A1 (en) * | 2002-03-11 | 2003-09-22 | TAYLOR, , Carla | Use of ppar alpha agonists for the treatment of vascular and renal diseases |
| US20070225614A1 (en) | 2004-05-26 | 2007-09-27 | Endothelix, Inc. | Method and apparatus for determining vascular health conditions |
| FR2845602B1 (fr) * | 2002-10-11 | 2005-07-08 | Servier Lab | Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent |
| GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| JP2005104951A (ja) * | 2003-01-17 | 2005-04-21 | Kirin Brewery Co Ltd | 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品 |
| FR2868313B1 (fr) * | 2004-03-31 | 2008-08-15 | Servier Lab | Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent |
| EP1621200A1 (en) * | 2004-07-26 | 2006-02-01 | Fournier Laboratories Ireland Limited | Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate |
| JP2008542389A (ja) | 2005-06-01 | 2008-11-27 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の状態の治療、およびエネルギーバイオマーカーの調節のための酸化還元活性治療薬 |
| WO2007035496A1 (en) | 2005-09-15 | 2007-03-29 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP1785133A1 (en) * | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| US7897326B2 (en) | 2006-03-16 | 2011-03-01 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Peroxisome-proliferator activated receptor-alpha agonists for organ preservation |
| US20070225606A1 (en) * | 2006-03-22 | 2007-09-27 | Endothelix, Inc. | Method and apparatus for comprehensive assessment of vascular health |
| US20080027330A1 (en) * | 2006-05-15 | 2008-01-31 | Endothelix, Inc. | Risk assessment method for acute cardiovascular events |
| US20080081963A1 (en) * | 2006-09-29 | 2008-04-03 | Endothelix, Inc. | Methods and Apparatus for Profiling Cardiovascular Vulnerability to Mental Stress |
| KR100989093B1 (ko) | 2008-01-18 | 2010-10-25 | 한화제약주식회사 | 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물 |
| CA2736250C (en) | 2008-09-10 | 2016-12-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2391219A4 (en) * | 2009-01-29 | 2013-03-06 | Joshua D Levine | METHOD FOR ADDING VEGETABLE SUBSTANCES / NUTRITIONAL AGGREGATES FOR PHARMACEUTICAL TREATMENT IN A PHARMACOTHERAPEUTIC TREATMENT |
| US8973851B2 (en) | 2009-07-01 | 2015-03-10 | The Procter & Gamble Company | Apparatus and methods for producing charged fluid droplets |
| US8772349B2 (en) * | 2010-03-26 | 2014-07-08 | Vivacell Biotechnology Espana, S.L. | Cannabinoid quinone derivatives |
| RU2554500C2 (ru) * | 2013-09-20 | 2015-06-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ лечения ишемического инсульта |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| US10881686B2 (en) | 2017-10-27 | 2021-01-05 | Zeta Biolongevity, Inc | Compositions and methods for treating and preventing proteinuria and endothelial erosion |
| CN110907407B (zh) * | 2019-12-03 | 2022-02-25 | 东北石油大学 | 一种基于spr的高灵敏度光子准晶体光纤折射率传感器 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229385A (en) | 1986-01-30 | 1993-07-20 | Takeda Chemical Industries, Ltd. | Quinone derivatives, their production and use |
| FR2627696B1 (fr) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| FI102273B1 (fi) | 1989-09-11 | 1998-11-13 | Eisai Co Ltd | Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyttö |
| FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
| US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| HUP0400931A2 (hu) | 1997-11-28 | 2004-07-28 | Karsanov, Nyikolai Vaszilievics | Hypoxia és ischaemia elleni gyógyszer |
| US6423742B1 (en) * | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
-
2001
- 2001-10-23 AU AU2176502A patent/AU2176502A/xx active Pending
- 2001-10-23 DK DK01988586T patent/DK1328266T3/da active
- 2001-10-23 SK SK508-2003A patent/SK287992B6/sk unknown
- 2001-10-23 PL PL361635A patent/PL212952B1/pl not_active IP Right Cessation
- 2001-10-23 IL IL15552401A patent/IL155524A0/xx active IP Right Grant
- 2001-10-23 PT PT01988586T patent/PT1328266E/pt unknown
- 2001-10-23 JP JP2002537311A patent/JP4236464B2/ja not_active Expired - Fee Related
- 2001-10-23 EE EEP200300165A patent/EE05281B1/xx not_active IP Right Cessation
- 2001-10-23 CZ CZ20031148A patent/CZ301282B6/cs not_active IP Right Cessation
- 2001-10-23 DZ DZ013442A patent/DZ3442A1/fr active
- 2001-10-23 US US10/399,639 patent/US7410983B2/en not_active Expired - Fee Related
- 2001-10-23 HU HU0303566A patent/HUP0303566A3/hu unknown
- 2001-10-23 KR KR1020037004793A patent/KR100862129B1/ko not_active Expired - Fee Related
- 2001-10-23 CA CA2426625A patent/CA2426625C/en not_active Expired - Fee Related
- 2001-10-23 AT AT01988586T patent/ATE316787T1/de active
- 2001-10-23 CN CNB01817972XA patent/CN1220488C/zh not_active Expired - Fee Related
- 2001-10-23 ES ES01988586T patent/ES2257457T3/es not_active Expired - Lifetime
- 2001-10-23 RU RU2003111175/15A patent/RU2003111175A/ru not_active Application Discontinuation
- 2001-10-23 EP EP01988586A patent/EP1328266B1/en not_active Expired - Lifetime
- 2001-10-23 DE DE60117046T patent/DE60117046T2/de not_active Expired - Lifetime
- 2001-10-23 BR BR0114701-3A patent/BR0114701A/pt not_active Application Discontinuation
- 2001-10-23 MX MXPA03003733A patent/MXPA03003733A/es active IP Right Grant
- 2001-10-23 WO PCT/EP2001/012425 patent/WO2002034259A1/en not_active Ceased
- 2001-10-25 TN TNTNSN01151A patent/TNSN01151A1/en unknown
- 2001-10-26 AR ARP010105032A patent/AR035071A1/es unknown
-
2003
- 2003-04-21 IL IL155524A patent/IL155524A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031851A patent/NO332260B1/no not_active IP Right Cessation
- 2003-04-25 MA MA27124A patent/MA25847A1/fr unknown
- 2003-04-25 BG BG107765A patent/BG65979B1/bg unknown
-
2006
- 2006-03-21 CY CY20061100400T patent/CY1105007T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035071A1 (es) | Compuestos para el tratamiento de la disfuncion endotelial; metodo para producir a dichos compuestos farmaceuticos; uso de dichos compuestos para la manufactura de un medicamento | |
| RU2004126950A (ru) | Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| MA28009A1 (fr) | Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques | |
| PA8446101A1 (es) | Derivados de acido arilsulfonil hidroxamico | |
| MA28011A1 (fr) | Derives de piperazine et leur utilisation en tant qu'agents therapeutiques | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| AR034270A1 (es) | 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| AR067824A1 (es) | Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer. | |
| MA28008A1 (fr) | Derives pyridyle et leur utilisation en tant qu'agents therapeutiques | |
| CO4940402A1 (es) | Sales de sertralina y formas de dosificacion de liberacion sostenida de sertralina | |
| AR036133A1 (es) | Pirazinas, formulacion farmaceutica, usos de estos compuestos para la manufactura de medicamentos, procesos para la preparacion de estos compuestos, y compuestos intermediarios | |
| DOP2001000270A (es) | Agonistas del receptor 3-adrenergico y usos de los mismos | |
| NO2012015I1 (no) | Dapoxetine i en hver form beskyttet av basis patent nr 330562 | |
| AR040971A1 (es) | Compuestos pirimido que tienen actividad antiproliferativa | |
| AR036100A1 (es) | Derivados de naftil benzofurano sustituidos, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos que son inhibidores del inhibidor-1 activador de plasminogeno (pai-1) | |
| RU94044671A (ru) | Применение непептидных антагонистов рецептора тахикинина | |
| CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| RU93005334A (ru) | Производные стероидов для лечения гипертрофии предстательной железы, способ их получения, использование, фармкомпозиция | |
| MA28742B1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique | |
| ECSP045469A (es) | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas | |
| MX9305947A (es) | Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
| MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR030007A1 (es) | Compuesto de ciclohexilo, su uso para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene, proceso para su preparacion, compuestos para su exclusivo uso en la preparacion de dichos compuestos de ciclohexilo, y metodo de tratamiento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |